CONCERT PHARMACEUTICALS, INC.
CONCERT PHARMACEUTICALS, INC. (CNCE): 4 pipeline candidates · ~17 mo cash runway. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
17.3 months
D/E 0.28 · 4% dilution
N/A
4 candidates
N/A
N/A
A transparent, data-derived signal for CONCERT PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$96.3M
Quarterly Burn
$26.0M
Runway
17.3 mo
Revenue
$8K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in CONCERT PHARMACEUTICALS, INC.'s pipeline?
CONCERT PHARMACEUTICALS, INC. (CNCE) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CONCERT PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CONCERT PHARMACEUTICALS, INC. has approximately 17.3 months of cash runway.
Who is the CEO of CONCERT PHARMACEUTICALS, INC.?
Massachusetts April is the chief executive officer of CONCERT PHARMACEUTICALS, INC. (CNCE).
Get the full picture on CONCERT PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.